Biofrontera Inc. BFRI
0.83 USD +0.02 (+2.50%)
At closeNov 6, 2026, 6:39 PM EST
0.88 +0.05 +6.28%
After hours · Nov 6, 6:39 PM ET
0.81 Day range 0.84
0.555 52-week range 1.66
- YTD
- +45.26%
- 1 year
- -28.62%
News
benzinga.com Biofrontera Refiles Supplemental New Drug Application For Ameluz Topical Gel To FDA To Treat Actinic Keratoses Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Flyte Aviation, Inc. Common Stock (AMEX:VJET) stock moved upwards by 34.0% to $2.17 during Monday's after-market session. Option Care Health (NASDAQ:OPCH) shares rose 20.92% to $28.26. The…
benzinga.com Transcript: Biofrontera Q2 2026 Earnings Conference Call On Thursday, Biofrontera (NASDAQ:BFRI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…
benzinga.com Biofrontera Receives FDA Supplemental New Drug Application Approval For Its Ameluz Topical Gel, 10%, In Combination With Photodynamic Therapy Using The BF-RhodoLED Lamp Series For The Treatment Of Superficial Basal Cell Carcinoma In Adults With this approval, Ameluz becomes the first and only PDT drug approved by the FDA for the treatment of a skin cancer, and the only topical PDT in the United States indicated to treat both a…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX)…
benzinga.com Biofrontera Q2 EPS $(0.05) Misses $(0.04) Estimate, Sales $12.003M Beat $10.500M Estimate Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 91.23 percent increase over losses of $(0.57)…
benzinga.com This Hanover Insurance Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday Wall Street analysts changed ratings on top names. Check our analyst ratings page for full updates. THG, BFRI covered.
benzinga.com This Stubhub Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. See what other analysts think of these stocks.
benzinga.com Benchmark Downgrades Biofrontera to Speculative Buy, Maintains Price Target to $3 Benchmark analyst Bruce D. Jackson downgrades Biofrontera (NASDAQ:BFRI) from Buy to Speculative Buy and maintains the price target from $3 to $3.- benzinga.com Transcript: Biofrontera Q1 2026 Earnings Conference Call
- benzinga.com Biofrontera Q1 EPS $(0.41) Misses $(0.12) Estimate, Sales $10.084M Miss $10.250M Estimate Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.12) by 272.73 percent. This is a 12.77 percent increase over losses of…
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com Biofrontera Q4 EPS $0.48 Beats $0.20 Estimate, Sales $17.100M Beat $16.146M Estimate Biofrontera (NASDAQ:BFRI) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.20 by 146.15 percent. This is a 352.63 percent increase over losses of $(0.19)…
- benzinga.com Earnings Scheduled For March 19, 2026
benzinga.com Biofrontera Announces US Patent Trial And Appeal Board Final Written Decision Finding All Challenged Claims Of Sun Pharma's '028 Patent To Be Unpatentable Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy ("PDT"), today announced that on February 23, 2026, the U.S.…
benzinga.com Biofrontera's Supplemental New Drug Application For Ameluz Accepted By FDA Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (PDT), today announced that…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Biofrontera Announces Results From 172 Participants In Its Phase 3 Cliical Study Of Ameluz Photodynamic Therapy To Treat Actinic Keratoses Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Biofrontera Expects Q4 Revenue Between $17M - $17.5M, FY25 Revenue Between $41.5M - $42M Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for…
benzinga.com Biofrontera Locks Databases For Treatment Phase Of Phase 3 Clinical Trial Of Ameluz PDT, Phase 2 Clinical Trial To Treat Moderate To Severe Acne Vulgaris Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Biofrontera Transfers Of Ameluz, RhodoLED New Drug Applications, Investigational New Drug Applications; Completes Requirements For Transfer Of All U.S., Some Global Intellectual Property Associated With Ameluz And RhodoLED Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced the completion of the transfer of the FDA…
- benzinga.com Biofrontera Completes Final Patient Visit In Phase 1 Pharmacokinetic Study Of Ameluz Gel, 10%, For Treatment Of Mild To Moderate Actinic Keratoses On Neck, Trunk And Extremities Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz® over treatment area of 240 cm2Completion of this study marks a key milestone…
- benzinga.com Biofrontera Files sNDA For Ameluz-PDT To Treat sBCC After Phase 3 Trial Achieves 65.5% Complete Clearance Of Main Target Lesions; Primary And Key Secondary Endpoints Met With High Statistical Significance With Favorable One-Year Recurrence and Aesthetic Outcomes sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to…
benzinga.com Biofrontera Q3 EPS $(0.62) Misses $(0.58) Estimate, Sales $6.988M Miss $7.000M Estimate Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.58) by 6.9 percent. This is a 36.73 percent increase over losses of $(0.98)…- benzinga.com Earnings Scheduled For November 12, 2025
benzinga.com Biofrontera Earnings Preview - benzinga.com Biofrontera Announces The Sale Of Its U.S. License For Xepi Cream To Pelthos Therapeutics. The Company Received $3M Upfront, Will Get $1M Upon Product Availability, And May Earn Up To $6M In Milestone Payments Tied To Future U.S. Sales Performance. Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further…
benzinga.com EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings.- benzinga.com Biofrontera Completes Treatment Phase In Phase 3 Trial Of Ameluz For Actinic Keratosis On Body; Supplemental New Drug Application Planned For Submission In Q2 2026 All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in October 2024 for use of up to 3 tubes of Ameluz® per treatmentStudy…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Biofrontera Completes Final Patient Visit In Phase 2b Acne Trial, Top-Line Results Expected Q1 2026; Plans FDA Discussion For Phase 3 In Q3 Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansionMore…
- benzinga.com Biofrontera Q2 EPS $(0.57) Misses $(0.42) Estimate, Sales $9.03M Beat $8.30M Estimate Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.42) by 35.71 percent. This is a 1040 percent decrease over losses of…
- benzinga.com Earnings Scheduled For August 13, 2025
benzinga.com A Look at Biofrontera's Upcoming Earnings Report - benzinga.com Biofrontera Inc. Acquires All US Rights To Ameluz And RhodoLED From Former Parent Co. Biofrontera AG, Coupled With $11M Financing Led Bt Existing Investors; Under New Agreement, Effective Royalty Rate Paid By Co. Will Be Reduced To 12% Of Net Sales Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz® and RhodoLED® including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG.Under…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Biofrontera Confirms Talks With Biofrontera AG On Potential Merger Or Deal Restructuring To Lower U.S. Product Costs Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), confirms a disclosure by the Management Board of…
- benzinga.com Biofrontera's Propylene Glycol-Free Ameluz Formulation Receives FDA Orange Book Listing Following April 2025 Patent Approval, Extending Protection Through 2043 Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through to December 2043.The Orange Book is published by the U.S. Food and Drug…
- benzinga.com Benchmark Maintains Buy on Biofrontera, Lowers Price Target to $2.75 Benchmark analyst Bruce Jackson maintains Biofrontera (NASDAQ:BFRI) with a Buy and lowers the price target from $7 to $2.75.
benzinga.com Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - benzinga.com Biofrontera Receives Patent Approval For Updated Formulation Of Ameluz Nanoemulsion Gel Without Propylene Glycol, Through To December 2043 Biofrontera has received patent approval for the revised formulation of Ameluz®, which extends patent protection through to December 2043Ameluz PDT offers the potential for effective treatment of…
- benzinga.com Earnings Scheduled For May 15, 2025
- benzinga.com An Overview of Biofrontera's Earnings